Get the Stockscreener App
335.19
2.35%
7.69
Krystal Biotech Inc stock is traded at $335.19, with a volume of 520.34K.
It is up +2.35% in the last 24 hours and down -3.58% over the past month.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
See More
Previous Close:
$327.50
Open:
$327.55
24h Volume:
520.34K
Relative Volume:
1.30
Market Cap:
$9.88B
Revenue:
$417.30M
Net Income/Loss:
$225.03M
P/E Ratio:
44.80
EPS:
7.4815
Net Cash Flow:
$237.38M
1W Performance:
-5.54%
1M Performance:
-3.58%
6M Performance:
+19.06%
1Y Performance:
+123.46%
1-Day Range:
$326.01
$338.58
1-Week Range:
$325.00
$360.98
52-Week Range:
$130.50
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
335.19 | 9.88B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech, Inc. (KRYS) stock price, news, quote and history - Yahoo Finance Singapore
Krystal Biotech, Inc. (KRYS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400Biotechnology - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) added to S&P 400 Health Care - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 Health Care - marketscreener.com
Krystal Biotech, Inc.(NasdaqGS: KRYS) dropped from S&P 600 - marketscreener.com
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 - The Manila Times
Krystal Biotech sets Aug. 3 webcast before U.S. markets open - Stock Titan
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 - GlobeNewswire Inc.
Krystal Biotech Reveals Single-Patient Data from Discontinued KB801 Trial in Patent Filing - Kalkine Media
Krystal BiotechFiles Response With Uspto On Kb801 Patent ApplicationSEC Filing - TradingView
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech (KRYS) Joins S&P MidCap 400 Amid Index Changes - GuruFocus
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Krystal Biotech Set to Enter S&P MidCap 400 as Two Join - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a $10 Billion Valuation and Strategic Growth in Genetic Medicine - DirectorsTalk Interviews
(KRYS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
KRYS Jumps As Wall Street Hikes Price Targets On Vyjuvek Momentum - StocksToTrade
KRYS Jumps As Analysts Race To Lift Price Targets - StocksToTrade
KRYS Jumps As Wall Street Lifts Bullish Price Targets - StocksToTrade
Krystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalysts - Quiver Quantitative
Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup - ChartMill
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396 - Moomoo
ETFs Investing in Krystal Biotech, Inc. Stocks - TradingView
KRYS Maintained by B of A Securities -- Price Target Raised to $396 - GuruFocus
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $369.44, Implies 1% Upside - TradingView
Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474 - Moomoo
BofA raises Krystal Biotech stock price target on Vyjuvek growth By Investing.com - Investing.com Nigeria
BofA raises Krystal Biotech stock price target on Vyjuvek growth - Investing.com
Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts - Sahm
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Is the options market predicting a spike in Krystal Biotech stock? - MSN
Here's why Krystal Biotech, Inc. (KRYS) is a strong momentum stock - MSN
Analysts see more upside for Abivax, Krystal Biotech, Marvell - MSN
3 Soaring Stocks That May Have More Upside Ahead - The Globe and Mail
Krystal Biotech focuses on gene-based dermatology treatments as investors watch long-term growth - ad-hoc-news.de
French gene therapy biotech gets €33M to follow Krystal’s blueprint - Endpoints News
Krystal Biotech, Inc. (KRYS) Stock Analysis: A High-Potential Biotech with Robust Revenue Growth and Strategic Therapeutic Pipeline - DirectorsTalk Interviews
KRYSKrystal Biotech Inc Options - Finviz
Price to book forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Krystal Biotech stock soars 16% in three months: Here's why - MSN
Krystal Biotech (KRYS) soars 3.4%: Is further upside left in the stock? - MSN
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Biotech Marvel with 31.9% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Krystal Biotech, Inc. Actuals & Estimates (NASDAQ:KRYS) - TradingView
Krystal Biotech, Inc. Actuals & Estimates (FWB:4KB) - TradingView
Form 4 Krystal Biotech Inc For: 26 June By Investing.com - Investing.com South Africa
Krystal Biotech, Inc. Actuals & Estimates (MIL:1KRYS) - TradingView
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):